entertainment -WSS

entertainment

author：comprehensive 2025-09-28 04:58:47 - browse：627

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Patients' immediate access to test results puts radiologists in a bind

hotspot

focus

WSS

Maisha Meds is a PBM, but don't call it that

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

FDA sets aggressive timeline for overhauling inspection procedures

Why sickle cell disease is getting the first CRISPR treatment

Dana Farber says 6 studies to be retracted and 31 corrected

The inclusion problem at the heart of rehabilitation research

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medicare details structure of new drug price negotiation program

STAT letters to the editor on burnt

Bright Health sells Medicare Advantage business to Molina

Patients' immediate access to test results puts radiologists in a bind

Drug repurposing or repositioning? The language matters

STAT letters to the editor on burnt

Malaria cases in Florida and Texas: Here’s what you need to know

FDA needs staff influx to meet gene therapy needs, Marks says

Dobbs anniversary: the lost opportunity of abortion as health care

A pediatrician calls for Congress to pass the child tax credit deal

hotspot

Leukemia patients are helped by Syndax's new type of therapy

Roche to buy Carmot Therapeutics, developer of obesity drugs

HPV vaccine, cervical cancer study delivers historic results

Dog Aging Project founders on what lies ahead after losing funding

Dog Aging Project founders on what lies ahead after losing funding

Inaction leaves children at risk from dangerous chemotherapy drug

knowledge

hotspot

focus

explore